Compare Heron Therapeutics Inc (HRTX) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Marqeta Inc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Marqeta Inc trades at $18.11 (market cap $1.82B). The key difference: Marqeta Inc is far larger — about 26.8× Heron Therapeutics Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Marqeta Inc for 44 Days on average.
| HRTX | MQ | |
|---|---|---|
Market Cap | $68.01M | $1.82B |
Volume | 1,891,941 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $1.49 | $20.32 |
52-Week Low | $0.27 | $15.04 |
Typical Hold Time | 35 Days | 44 Days |
Enterprise Value | $174.75M | $1.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
Marqeta (MQ) trades at $18.11, up 6.15% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while revenue grew 23% year-over-year to $625M in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. However, valuation remains elevated with a P/E of 193.83 and negative EBITDA of -$19.27M despite improving cash flow trends.
Outlook remains mixed with analyst consensus at Hold (59% of ratings) and a $11.38 price target suggesting 37% downside. Key risks include contract renewals in Q3 2026 potentially slowing growth, while institutional sentiment is cautious despite technical strength. The stock's premium valuation requires sustained execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
